Altimmune, Inc.
ALT
$4.07
$0.071.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.11% | -95.12% | -95.31% | -81.36% | 604.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.11% | -95.12% | -95.31% | -81.36% | 604.94% |
| Cost of Revenue | -6.79% | 9.32% | 24.97% | 16.58% | 11.43% |
| Gross Profit | 6.32% | -9.94% | -25.75% | -16.98% | -10.72% |
| SG&A Expenses | 10.07% | 14.43% | 15.60% | 14.75% | 12.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.38% | 10.41% | 22.94% | 16.20% | 11.61% |
| Operating Income | 2.99% | -10.90% | -23.54% | -16.52% | -11.04% |
| Income Before Tax | 12.75% | 1.99% | -7.48% | -31.93% | -24.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.42% | 2.72% | -7.48% | -31.93% | -24.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.42% | 2.72% | -7.48% | -31.93% | -24.64% |
| EBIT | 2.99% | -10.90% | -23.54% | -16.52% | -11.04% |
| EBITDA | 2.72% | -11.30% | -23.98% | -17.29% | -11.50% |
| EPS Basic | 27.25% | 21.09% | 18.58% | -1.24% | 0.53% |
| Normalized Basic EPS | 15.61% | 8.25% | 6.50% | 12.60% | 13.80% |
| EPS Diluted | 27.25% | 21.09% | 18.58% | -0.69% | 1.21% |
| Normalized Diluted EPS | 15.61% | 8.25% | 6.50% | 12.60% | 13.80% |
| Average Basic Shares Outstanding | 17.95% | 23.65% | 33.43% | 32.66% | 26.82% |
| Average Diluted Shares Outstanding | 17.95% | 23.65% | 33.43% | 32.66% | 26.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |